Excellent response to tofacitinib treatment in a patient with alopecia universalis
| Autor: | Ahmet Burhan Aksakal, Funda Erduran, Esra Adişen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences Young Adult 0302 clinical medicine Piperidines Female patient medicine Humans Pyrroles Protein Kinase Inhibitors Tofacitinib integumentary system business.industry Treatment options Alopecia Alopecia areata medicine.disease 030104 developmental biology Infectious Diseases medicine.anatomical_structure Pyrimidines Alopecia universalis Scalp Female Janus kinase business |
| Popis: | Alopecia universalis (AU) is generally considered a variant of alopecia areata (AA), in which the treatment options seldom provide satisfactory results. However, successful treatment of several cases of AA and its variants with oral Janus kinase (JAK) inhibitors have been reported recently. Here we report a 23-year-old female patient with AU successfully treated with tofacitinib, a selective JAK-3 inhibitor. The initial tofacitinib dose was 5 mg twice daily. After 2 months of treatment, partial hair regrowth was seen on the scalp and eyebrows. Thereafter, the dose was increased to 10 mg in the morning and 5 mg at night. By 6 months of the treatment, there was complete hair regrowth throughout the entire body. Our patient tolerated tofacitinib well, without any significant side effects. Tofacitinib emerges as a promising novel therapy in alopecia universalis. We believe further study is required to establish the safety and confirm the efficacy of tofacitinib treatment for alopecia universalis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|